Number needed to treat in COPD: Exacerbations versus pneumonias

Thorax

Volumn 68, Issue 6, 2013, Pages 540-543

  Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; LONG ACTING DRUG; SALMETEROL;

ARTICLE; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NUMBERS NEEDED TO TREAT; PNEUMONIA; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84877599739     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202709     Document Type: Article

References (20)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
2. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.
3. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9. (Pubitemid 46115085)
4. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
5. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108.
6. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9.
7. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-29.
8. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16.
9. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-12.
10. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
11. Halpin DM. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005;59:1187-94. (Pubitemid 43904526)
12. Aaron SD, Fergusson DA. Exaggeration of treatment benefits using the 'event-based' number needed to treat. CMAJ 2008;179:669-71.
13. Suissa S. Calculation of number needed to treat. N Engl J Med 2009;361:424-5.
14. Suissa D, Brassard P, Smiechowski B, et al. Number needed to treat is incorrect without proper time-related considerations. J Clin Epidemiol 2012;65:42-6.
15. McAlister FA. The 'number needed to treat' turns 20-and continues to be used and misused. CMAJ 2008;179:549-53.
16. Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall, 1994.
17. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. Br Med J 1999;319:1492-5.
18. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:369-74.
19. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
20. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-63.